SGC-CK2-1 is an ATP-competitive chemical compound that acts as a highly potent and cell-active CK2 inhibitor. It demonstrates excellent selectivity towards both isoforms of human CK2, with IC50 values of 36 nM for CK2α and 16 nM for CK2α′ in the nanoBRET assay. Given its properties, SGC-CK2-1 is a suitable tool for the investigation of neurodegenerative diseases.

SGC-CK2-1 is a potent inhibitor of CSNK2A2 and CSNK2A1, demonstrating IC50 values of 2.3 nM and 4.2 nM, respectively[1]. Additionally, it exhibits an inhibitory effect on DYRK2 with an IC50 value of 3.7 μM[1]. The compound effectively inhibits a range of blood cancer cell lines, including U-937, MV4-11, MOLM-13, OCI-LY19, and OCI-AML5, with IC50 values ranging from 120 nM to 810 nM. It also shows notable inhibitory activities against various cancer cells from different origins: Head/Neck Detroit562, Lung NCI-H2286, Brain SK-N-MC, Breast BT-20, Skin A375, Stomach SNU-1, and Duodenum Hutu 80 cells, with IC50 values varying from 550 nM to 920 nM[1].